Extension of Time to File SOU

INGREZZA

Neurocrine Biosciences, Inc.

Request for Extension of Time to File a Statement of Use

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88161461
LAW OFFICE ASSIGNED LAW OFFICE 113
MARK SECTION
MARK http://uspto.report/TM/88161461/mark.png (stylized and/or with design)
STANDARD CHARACTERS NO
USPTO-GENERATED IMAGE NO
OWNER SECTION (current)
NAME Neurocrine Biosciences, Inc.
MAILING ADDRESS 12780 El Camino Real
CITY San Diego
STATE California
ZIP/POSTAL CODE 92130
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
OWNER SECTION (proposed)
NAME Neurocrine Biosciences, Inc.
MAILING ADDRESS 12780 El Camino Real
CITY San Diego
STATE California
ZIP/POSTAL CODE 92130
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME B. Brett Heavner
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE docketing@finnegan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
CORRESPONDENCE INFORMATION (proposed)
NAME B. Brett Heavner
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE docketing@finnegan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
DOCKET/REFERENCE NUMBER 14640.1003
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations for human use for schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and Tourette syndrome, movement disorders, namely, Myoclonus, Huntington's chorea, Levodopa-induced dyskinesia, tardive dyskinesia, dystonia, and tics
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 2
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 11/12/2019
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /David L. Bradfute/
SIGNATORY'S NAME David L. Bradfute, PhD, JD
SIGNATORY'S POSITION Vice President & Head, Intellectual Property
DATE SIGNED 11/01/2020
SIGNATORY'S PHONE NUMBER 202-408-4000 (Applicant's attorney)
FILING INFORMATION
SUBMIT DATE Mon Nov 02 12:22:38 ET 2020
TEAS STAMP USPTO/ESU-XX.XXX.X.X-2020
1102122238693759-88161461
-750be2f8df14d6982d85c776
b6543d3f987b87a6ef7d5ec3a
acf90a5ac5e237040-CC-2237
1671-20201030135622799380



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: INGREZZA (stylized and/or with design, see http://uspto.report/TM/88161461/mark.png)
SERIAL NUMBER: 88161461

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Neurocrine Biosciences, Inc., having an address of
      12780 El Camino Real
      San Diego, California 92130
      United States
      Email: XXXX
Proposed: Neurocrine Biosciences, Inc., having an address of
      12780 El Camino Real
      San Diego, California 92130
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 11/12/2019.

For International Class 005:
Current identification: Pharmaceutical preparations for human use for schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and Tourette syndrome, movement disorders, namely, Myoclonus, Huntington's chorea, Levodopa-induced dyskinesia, tardive dyskinesia, dystonia, and tics

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current):
      B. Brett Heavner
      PRIMARY EMAIL FOR CORRESPONDENCE: docketing@finnegan.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      B. Brett Heavner
      PRIMARY EMAIL FOR CORRESPONDENCE: docketing@finnegan.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /David L. Bradfute/      Date Signed: 11/01/2020
Signatory's Name: David L. Bradfute, PhD, JD
Signatory's Position: Vice President & Head, Intellectual Property
Signatory's Phone: 202-408-4000 (Applicant's attorney)

RAM Sale Number: 88161461
RAM Accounting Date: 11/02/2020

Serial Number: 88161461
Internet Transmission Date: Mon Nov 02 12:22:38 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.X.X-2020110212223869375
9-88161461-750be2f8df14d6982d85c776b6543
d3f987b87a6ef7d5ec3aacf90a5ac5e237040-CC
-22371671-20201030135622799380




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed